Literature DB >> 23684562

Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure.

Marie-France Seronde1, Etienne Gayat, Damien Logeart, Johan Lassus, Said Laribi, Riadh Boukef, Franck Sibellas, Jean-Marie Launay, Philippe Manivet, Malha Sadoune, Semir Nouira, Alain Cohen Solal, Alexandre Mebazaa.   

Abstract

BACKGROUND: We compared diagnostic and prognostic properties of brain natruiretic peptide (BNP), proBNP, NT-proBNP and MR-pro-atrial natriuretic peptide (ANP) in patients admitted with shortness of breath (SOB).
METHODS: All 4 NPs were measured in patients admitted to the emergency unit with SOB (in 2 centers) or acute heart failure (AHF) (1 FINN-AKVA cohort) and in a control population of stable chronic HF. Follow-up was 1 (2 centers) and 5 years (1 FINN-AKVA cohort). Area under the curve (AUC) was used to assess diagnostic properties. AUC, multivariate Cox regression, net reclassification improvement (NRI), and Kaplan-Meier analyses were used to assess mortality.
RESULTS: We included 710 patients ("Biomarcoeurs" cohort n=336; FINN-AKVA study, n=306; stable chronic HF, n=68). Pro-BNP was almost as powerful as BNP to diagnose AHF (AUC 0.953 vs 0.973 respectively, p=0.003), NT-proBNP also performed well (0.922, p<0.001 vs BNP). MR-proANP performed less well (0.901). AUC over time showed greater MR-proANP values over the first year. At 5 years, MR-proANP had the best prognostic value (AUC 0.668 vs 0.604 for BNP, p=0.042). Kaplan Meier analysis confirmed better survival with MR-proANP≤416.8 pmol/L at 5 years. NRI at 5 years was greater for MR-proANP (0.23, p<0.05) than for proBNP, BNP or NTproBNP (p=NS).
CONCLUSION: Our study provides firm evidence that all NPs perform equally well for diagnostic purposes, and that MR-proANP has long term prognostic value in patients with acute heart failure.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Acute heart failure; Atrial-type natriuretic peptides; B-type natriuretic peptides; Diagnosis; Prognosis

Mesh:

Substances:

Year:  2013        PMID: 23684562     DOI: 10.1016/j.ijcard.2013.04.164

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  19 in total

Review 1.  Natriuretic peptides in cardiovascular diseases: current use and perspectives.

Authors:  Massimo Volpe; Speranza Rubattu; John Burnett
Journal:  Eur Heart J       Date:  2013-11-13       Impact factor: 29.983

Review 2.  Biomarkers for risk prediction in acute decompensated heart failure.

Authors:  A Rogier van der Velde; Wouter C Meijers; Rudolf A de Boer
Journal:  Curr Heart Fail Rep       Date:  2014-09

3.  Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.

Authors:  Ioanna Koniari; Eleni Artopoulou; Dimitrios Velissaris; Mark Ainslie; Virginia Mplani; Georgia Karavasili; Nicholas Kounis; Grigorios Tsigkas
Journal:  J Geriatr Cardiol       Date:  2021-11-28       Impact factor: 3.327

4.  Identification of nondiabetic heart failure-associated genes by bioinformatics approaches in patients with dilated ischemic cardiomyopathy.

Authors:  Anzhong Yu; Jingyao Zhang; Haiyan Liu; Bing Liu; Lingdong Meng
Journal:  Exp Ther Med       Date:  2016-04-11       Impact factor: 2.447

5.  Heart 'omics' in AGEing (HOMAGE): design, research objectives and characteristics of the common database.

Authors:  Lotte Jacobs; Lutgarde Thijs; Yu Jin; Faiez Zannad; Alexandre Mebazaa; Philippe Rouet; Florence Pinet; Christophe Bauters; Burkert Pieske; Andreas Tomaschitz; Mamas Mamas; Javier Diez; Kenneth McDonald; John G F Cleland; Hans-Peter Brunner-La Rocca; Stephane Heymans; Roberto Latini; Serge Masson; Peter Sever; Christian Delles; Stuart Pocock; Timothy Collier; Tatiana Kuznetsova; Jan A Staessen
Journal:  J Biomed Res       Date:  2014-07-31

6.  Renal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives.

Authors:  João Pedro Ferreira; Nicolas Girerd; Pierpaolo Pellicori; Kevin Duarte; Sophie Girerd; Marc A Pfeffer; John J V McMurray; Bertram Pitt; Kenneth Dickstein; Lotte Jacobs; Jan A Staessen; Javed Butler; Roberto Latini; Serge Masson; Alexandre Mebazaa; Hans Peter Brunner-La Rocca; Christian Delles; Stephane Heymans; Naveed Sattar; J Wouter Jukema; John G Cleland; Faiez Zannad; Patrick Rossignol
Journal:  BMC Med       Date:  2016-11-10       Impact factor: 8.775

7.  Percutaneous Closure of Left Atrial Appendage affects Mid-Term Release of MR-proANP.

Authors:  Michael Behnes; Benjamin Sartorius; Annika Wenke; Siegfried Lang; Ursula Hoffmann; Christian Fastner; Martin Borggrefe; Thomas Roth; Jakob Triebel; Thomas Bertsch; Ibrahim Akin
Journal:  Sci Rep       Date:  2017-08-22       Impact factor: 4.379

Review 8.  Resetting the neurohormonal balance in heart failure (HF): the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF.

Authors:  Speranza Rubattu; Filippos Triposkiadis
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

9.  RNA sequencing analysis and atrial natriuretic peptide production in patients with dilated and ischemic cardiomyopathy.

Authors:  Estefanía Tarazón; Esther Roselló-Lletí; Miguel Rivera; Ana Ortega; Maria Micaela Molina-Navarro; Juan Carlos Triviño; Francisca Lago; José Ramón González-Juanatey; Placido Orosa; José Anastasio Montero; Antonio Salvador; Manuel Portolés
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

10.  Diagnostic Accuracy of NT-ProBNP for Heart Failure with Sepsis in Patients Younger than 18 Years.

Authors:  Chun-Wang Lin; Wen Tang; Fang Wen; Jin-Jin Chen; Xiang-Lin Zeng; Zong-Geng Chen
Journal:  PLoS One       Date:  2016-01-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.